News

Blog y noticias

Maria-simo-webinar-3-1200x675.png

Maria Simó will be the first guest to the webinar cycle organized by Dr+Vet.

Dr+vet begins a new stage with the presentation of its training webinars for clinical veterinarians. The objective of these talks is to offer quality, enjoyable and useful training to clinicians interested in the world of veterinary ophthalmology.

In this first webinar, we will focus on Keratoconjunctivitis Sicca, since it is a relatively common eye disease in daily clinical practice. We will answer the main questions: How to diagnose it correctly? What are the most effective treatments to manage this eye disease?

The speaker:

Maria Simó, a prominent veterinary ophthalmologist with extensive experience in the diagnosis and treatment of eye diseases in animals. Graduated in Veterinary Medicine from the Autonomous University of Barcelona in 2016, Maria has completed the BSAVA Postgraduate Certificate in Small Animal Ophthalmology and has completed the ACVO Basic Science Course. Since 2020, she has worked as an ophthalmologist at the Veterinary Ophthalmological Institute (IVO) of Barcelona, where she works alongside Paco Simó, focued in veterinary ophthalmology.

Content:

Keratoconjunctivitis Sicca (KCS) is an inflammatory condition of the ocular surface, affecting both the cornea and the conjunctiva. It develops as a result of a deficiency in one of the phases of the tear film, and in dogs, its prevalence reaches 0.4%. However, the qualitative form of KCS (also known as Dry Eye Disease, DDE) often goes unnoticed in general practice, since the results of the Schirmer test (STT-1) usually show values within normality.

A gift for attendees:

All those registered for the seminar will automatically enter a draw to win a complete batch of Dr+Vet ophthalmological products, which will include: Glauco+, Occulus+, Lacrimalis+ 30 tablets, Lacrimalis+ 75ml, Retinae and Lintum. This prize will be drawn in the days close to the webinar through Dr+Vet’s Instagram.

Webinar Details:

Topic: Keratoconjunctivitis Sicca: Diagnosis and Treatment
Date: April 3, 2024
Time: 1:00 p.m. (CET)
Duration: 90 minutes (60 minutes of presentation, 30 minutes of questions and answers)
Speaker: María Simó

This webinar will be an invaluable opportunity to acquire new knowledge and techniques to address Keratoconjunctivitis Sicca in your patients! Don’t miss the opportunity to learn from an expert in the field and get your questions answered directly.

Register now at this link We are waiting for you!

For more information, contact us at drvet@groupandersen.com

See you at the webinar!


2.-post-seovet-linkedin-i-ig-e1707819252745.png

Dr+Vet will be an official collaborator of the next SEOVET Congress, the leading event for Spanish veterinarians specialized in ophthalmology.

This congress, organized by the Spanish Society of Veterinary Ophthalmology, will take place on February 23 and 24 at the Ilunión Pío XII Hotel in Madrid.

As a sponsor, Dr+Vet will have a stand where we will present the latest developments in our ophthalmological line. Among them, we want to highlight the improvements in two of our ophthalmic products: Occulus+, designed to help animals suffering from cataracts, now contains alpha lipoic acid (a powerful antioxidant), and Glauco+, a supplement for the optic nerve and retina in cases of glaucoma, now includes Citicoline (a powerful neuroprotector).

These products were presented at the last AVEPA-SEVC 2023 and have been on the market during the winter of 2023. At this congress, we are especially excited to be able to present the products directly to a specialist audience since it will be very interesting to receive their feedback direct and share knowledge and opinions.

We will give the specialists who visit our stand a cobalt blue light for examining fluorescein tests in addition to a 4+1 on our products.

We hope to see and meet other specialists and people interested in the world of veterinary ophthalmology like us.


Disseny-sense-titol.png

Progressive retinal atrophy is a degenerative ophthalmological condition that affects photoreceptors in the retina and constitutes a significant clinical challenge in veterinary practice.
This hereditary disease affects both dogs and cats, and is more common in large breed dogs.

Anatomically there are two types of photoreceptor neurons: rods, located in the periphery, and cones, located in the center. In this disease there is a progressive loss of these photoreceptors that compromises the retina’s ability to capture light, resulting in the gradual loss of the animal’s visual function, since visual information cannot be transmitted efficiently to the brain. Its initially very subtle onset makes early detection challenging and owners often do not notice the disease until it is in an advanced stage.

This condition, with a hereditary origin, affects both eyes equally, showing a certain predilection for specific breeds, such as the Poodle, Cocker, Labrador, Golden Retriever or the Bichon Maltese, although it can manifest itself in any breed and animal species (see table 1 ).

Table 1. Breeds genetically predisposed to suffer from degenerative retinal atrophy.

 

Akita Doberman Rottweiler
Alaskan malamute Fox terrier Schnauzer miniatura
Basset hound Gran danés San Bernardo
Beagle Greyhound italiano Samoyedo
Border Collie Golden retriever Schnauzer gigante
Border Terrier Husky siberiano Scottish terrier
Bóxer Labrador retriever Shih tzu
Bull Mastiff Bichón maltés Spitz
Bull terrier Pastor belga malinois Spaniel tibetano
Chihuahua Pastor alemán Setter irlandés
Caniche Perro de agua portugués Setter inglés
Rough collie Pequinés Setter gordon
Cocker spaniel inglés Pointer Springer spaniel inglés
Cocker spaniel americano Pomerania Terrier tibetano
Carlino Papillón Teckel

When does the disease appear?

Progressive retinal atrophy tends to manifest from the age of 8, but degeneration begins its course from 2-3 years of age. The initial symptoms are usually linked to the dysfunction of the rods, which are the first photoreceptors to deteriorate and are responsible for night vision. In dim light conditions, dogs may show difficulty seeing well, showing greater insecurity in their behavior. Owners may notice this phenomenon during night walks.

Animals experience difficulties perceiving objects and have dilated pupils in response to the lack of light perception. In many cases, progressive retinal atrophy is associated with the development of cataracts; These develop due to eye damage caused by substances produced by the degenerated retina.

How is it diagnosed?

The diagnosis of the disease requires validation from the veterinarian. It is recommended to perform annual visual checkups, especially in breeds predisposed to this disease.

The essential diagnostic tests to diagnose progressive retinal atrophy will be ophthalmoscopy to view the fundus of the eye and electrorenitography to assess the response of the retinal photoreceptors.

Which is the treatment?

In terms of treatment, it is crucial to highlight that progressive retinal atrophy lacks curative options, given its degenerative nature. However, there are therapeutic approaches that can slow down its progression, emphasizing the importance of early diagnosis to start treatment as soon as possible. Carrying out periodic checkups on pets, especially in predisposed breeds and in dogs that have suffered cataracts in their youth, is essential, since both pathologies are sometimes interrelated.

Therapeutic options include peripheral vasodilators, vitamins and lutein supplements such as Retinae from Dr+Vet. These supplements seek to provide support that, although it does not reverse the condition, can improve the patient’s quality of life and prolong their visual capacity. In this context, specialized veterinary care plays a fundamental role in the comprehensive management of progressive retinal atrophy, providing owners with guidance and care tailored to the specific needs of each patient.

This text is for informational purposes only. We suggest that you take your pet to the veterinarian in case it shows any discomfort similar to those mentioned in the article.


Copyright by Boothmen Pharma 2023. All rights reserved.